BCM
ZYNE

BlueCrest Capital Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

BlueCrest Capital Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-16,194
Closed -$132K – 1521
2018
Q3 		$132K Sell
16,194
-65,396
-80% -$502K ﹤0.01% 1356
2018
Q2 		$795K Buy
+81,590
New +$836K 0.02% 613

Other funds holding ZYNE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Campbell Capital Management Miami, Florida $279M AUM 49.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlueCrest Capital Management's ZYNE Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2018, closing a stake of 16,194 shares — an estimated $132K sold.

BlueCrest Capital Management first reported a position in ZYNE in Q2 2018 and held it in 2 quarters. The position peaked at $795K in Q2 2018. 62 funds tracked by Wall St. Rank hold ZYNE as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 16,194 Zynerba Pharmaceuticals, Inc shares in Q4 2018, an estimated $132K.
  • BlueCrest Capital Management first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2018 and held it in 2 quarters.
  • BlueCrest Capital Management's Zynerba Pharmaceuticals, Inc position peaked at $795K in Q2 2018.
  • 62 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.